If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. I last covered Amgen (NASDAQ: AMGN ) for Seeking Alpha in early August, reviewing the California based Pharma giant's Q2 earnings. I gave its stock a "Buy" rating, however ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $5.11 per share in its forthcoming report, representing an increase of 3% year over year. Revenues are projected to reach $8.52 billion, increasing 23.4% from the same quarter last year. The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates duri ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conferenc ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Prolia & Xgeva (denosumab).This product consists of: Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.Projec ...

Amgen (AMGN) will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company beat earnings expectations by 0.81%.The Zacks Consensus Estimate for sales and earnings is pegged at $8.51 billion and $5.11 per share, respectively.Factors to Consider for AmgenAmgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia and Blincyto among others. However, prices of most products are expected to continue to ...

This biotech leader could be poised to rally higher.Amgen (AMGN -0.09%) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant and Dow Jones Industrial Average component, pending clinical-trial data from its drug pipeline has added a layer of uncertainty.On the other hand, the company continues to deliver strong growth with overall positive fundamentals. So is now a good time to pick up so ...

The latest trading session saw Amgen (AMGN) ending at $325.09, denoting a +0.14% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%.Shares of the world's largest biotech drugmaker have depreciated by 3.17% over the course of the past month, outperforming the Medical sector's loss of 3.35% and lagging the S&P 500's gain of 4.31%.The investment comm ...

MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ PatientsFirst and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Corticosteroid UseTHOUSAND OAKS, Calif., Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) for the treatment of adults with generalized myasthenia gravis (gMG), a ...

Income stocks can be wise additions to your portfolio in any market environment.Dividend stocks can be a great way to supplement your portfolio growth from share price gains and inject more cash into your overall returns. Whether you use that cash to reinvest or put it aside for a rainy day, dividend stocks can be an excellent addition to any portfolio and for investors with a variety of investment styles.If you're hunting for two top dividend stocks to add to your portfolio right now, here are a couple of ...

These longtime leading biotech stocks still have plenty of upside ahead.October typically isn't a time investors look forward to in the markets. It has historically been associated with equities moving in the wrong direction, and sometimes experiencing full-blown market crashes. The broader market has performed pretty well so far this year, but could that come to a halt in October? Maybe.No matter what happens, investing in companies that will get through bear markets and perform well over the long run is a ...